SLC5A2 and diabetes mellitus: A meta-analysis of four CVOTs (EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI 58) including a total of 38,723 participants with diabetes found a 35% risk reduction of end-stage kidney disease (RR, 0.65; 95%CI, 0.53–0.81) in SGLT2-i users (Neuen et al., 2019).